Behcet's Disease Clinical Trial
Official title:
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations. Patients with Behçet's disease (BD), idiopathic inflammatory myopathy (IIM, also known as myositis) and IgG4-related disease (IgG4-RD) are treated with high-dosed glucocorticoids, methotrexate, azathioprine and mycophenolate mofetil, mostly for long periods of time with attendant risks of long-term toxicity, including infections. Therefore, there is an urgent need for new, more specific anti-inflammatory therapies such as targeted synthetic and biological disease-modifying antirheumatic drugs. Due to the role of type 1 interferon in both BD, IIM and IgG4-RD, JAK-STAT inhibition may be a promising treatment strategy in these conditions, because JAK1 is critical for the signal transduction of pro-inflammatory cytokine receptors. Previous research showed that JAK1 inhibition reduces activation of type 1 interferon-regulated proteins and key chemokines that control tissue inflammation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT04208464 -
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
|
Phase 2 | |
| Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06316076 -
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
|
Phase 1 | |
| Not yet recruiting |
NCT06350110 -
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05879419 -
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
|
Phase 4 | |
| Recruiting |
NCT04792931 -
Adult Autoimmune Myopathies (MAIA)
|
N/A | |
| Not yet recruiting |
NCT06417398 -
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
|
Early Phase 1 | |
| Recruiting |
NCT04664465 -
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
|
||
| Not yet recruiting |
NCT06152172 -
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
|
Phase 1 | |
| Recruiting |
NCT05400889 -
Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies
|
Phase 2 | |
| Completed |
NCT03918356 -
Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies
|
N/A | |
| Completed |
NCT00341679 -
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
|
||
| Recruiting |
NCT05952531 -
Characterizing Myositis With 68Ga-FAPI PET/CT
|
Early Phase 1 | |
| Recruiting |
NCT05200702 -
Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders
|
N/A | |
| Completed |
NCT03092167 -
Physical Training in Patients With Idiopathic Inflammatory Myopathies
|
N/A | |
| Recruiting |
NCT03092180 -
Optimizing Treatment on Idiopathic Inflammatory Myopathies
|
||
| Recruiting |
NCT05199246 -
Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders
|
N/A | |
| Not yet recruiting |
NCT04034199 -
Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
|
Phase 3 |